| Identification | Back Directory | [Name]
CAY10704 | [CAS]
101784-44-5 | [Synonyms]
CAY10704
CAY10704,CAY-10704
Piperazine, 1-[bis(4-chlorophenyl)methyl]-4-methyl- | [Molecular Formula]
C18H20Cl2N2 | [MOL File]
101784-44-5.mol | [Molecular Weight]
335.27 |
| Hazard Information | Back Directory | [Description]
CAY10704 is a potent inhibitor of hepatitis C virus (HCV) infection (EC50 = 17 nM) that displays low cytotoxicity of virally-infected human hepatoma Huh7.5.1 cells (CC50 = 21.3 μM).1 It displays good pharmacokinetics in mice when delivered intraperitoneally, with preferential liver distribution without significant hepatotoxicity.1 CAY10704 is selective for HCV over dengue virus (EC50 = 4.62 μM).1 | [Uses]
Antiviral agent 52 (Compound 30) is a Chlorcyclizine (HY-112067) derivative that exhibits antiviral activity against hepatitic C virus (HCV) with an EC50 of 17 nM. Antiviral agent 52 reveals cytotoxicity in cell Huh7.5.1 with CC50 of 21.3 μM[1]. | [in vivo]
Antiviral agent 52 (10 mg/kg, i.p.) is preferentially in liver distributed without significant hepatotoxicity[1].
Pharmacokinetic Analysis of Antiviral agent 52 in CD-1 mouse[1]
| - | plasma | liver | liver/plasma | | AUClast (μM·h) | 27.5 | 429 | 16 | | AUCINF (μM·h) | 29.8 | 495 | 17 | | T1/2 (h) | 6.7 | 8.5 | - | | Tmax (h) | 0.083 | 0.083 | - | | Cmax (h) | 5.28 | 57.0 | 11 |
| [References]
1. He, S., Xiao, J., Dulcey, A.E., et al. Discovery, optimization, and characterization of novel chlorcyclizine derivatives for the treatment of hepatitis C virus infection J. Med. Chem. 59(3),841-853(2016). |
|
|